8-K: Cue Biopharma Announces First Quarter 2025 Financial Results and Strategic Collaboration with Boehringer Ingelheim

Cue Biopharma reported its first quarter 2025 financial results, highlighted by a strategic collaboration with Boehringer Ingelheim and a follow-on capital raise.

Summary

• Cue Biopharma announced its first quarter 2025 financial results on May 12, 2025.
• The company reported revenue of $0.4 million for the quarter, compared to $1.7 million in the same period of 2024, due to the termination of the agreement with Ono Pharmaceutical in March 2025.
• Research and development expenses decreased to $8.5 million from $10.2 million year-over-year, primarily due to lower clinical trial costs and employee compensation.
• General and administrative expenses remained stable at $4.2 million.
• The company's net loss was $12.257 million, slightly better than the $12.347 million loss in the first quarter of 2024.
• As of March 31, 2025, Cue Biopharma had $13.1 million in cash and cash equivalents.
• Subsequently, the company raised approximately $18 million in net proceeds from an underwritten public offering in April 2025.
• They also received an upfront payment of $12 million from Boehringer Ingelheim as part of a strategic collaboration and license agreement for CUE-501, announced on April 14, 2025.
• A virtual event featuring key opinion leaders is planned for May 15, 2025, to discuss preclinical data for CUE-401 and updates on the CUE-500 and CUE-100 programs.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the strategic collaboration and capital raise, which are counterbalanced by the revenue decline and ongoing losses.

Positives

• Cue Biopharma secured a strategic collaboration with Boehringer Ingelheim for CUE-501, including an upfront payment of $12 million and potential milestone payments of ~$345 million.
• The company successfully raised approximately $18 million in net proceeds through an underwritten public offering in April 2025.
• Cue Biopharma regained worldwide rights for its lead autoimmune program, CUE-401, which has the potential to become a new standard of care.
• Research and development expenses decreased, indicating improved cost management.
• The net loss was slightly reduced compared to the same quarter last year.

Negatives

• Revenue decreased significantly from $1.7 million in Q1 2024 to $0.4 million in Q1 2025 due to the termination of the Ono Pharmaceutical agreement.
• The company reported a net loss of $12.257 million for the quarter.
• Cash and cash equivalents decreased from $22.459 million at the end of 2024 to $13.1 million as of March 31, 2025, before the capital raise and Boehringer Ingelheim payment.

Risks

• The company has a limited operating history and a history of losses.
• Cue Biopharma's ability to obtain adequate financing to fund its business operations is a concern.
• There are potential setbacks in research and development efforts, including negative or inconclusive results from preclinical studies or clinical trials.
• The company faces the risk of serious and unexpected drug-related side effects or other safety issues in clinical trials.
• Securing required FDA or other governmental approvals for product candidates is uncertain.
• The company relies on licensors, collaborators, contract research organizations, suppliers, and other business partners.
• Maintaining and enforcing necessary patent and other intellectual property protection is crucial.
• Competitive factors and general economic and market conditions pose risks.

Future Outlook

The company plans to advance CUE-401 toward the clinic and explore additional portfolio optimization and partnering opportunities.

Management Comments

• Daniel Passeri, chief executive officer of Cue Biopharma, stated that the company made notable and encouraging progress during the first quarter of 2025.
• He believes the strategic collaboration with Boehringer Ingelheim and the capital raise place the company in a position of strength.

Industry Context

Cue Biopharma's focus on T-cell modulation aligns with the growing interest in immunotherapy for both cancer and autoimmune diseases. The collaboration with Boehringer Ingelheim validates the potential of Cue Biopharma's Immuno-STAT platform. Regaining rights to CUE-401 positions them to capitalize on the autoimmune market.

Comparison to Industry Standards

• The $12 million upfront payment from Boehringer Ingelheim for CUE-501 is within the typical range for early-stage collaboration agreements in the biotech industry.
• Similar companies like Xencor and Compass Therapeutics are also focused on developing T-cell engaging therapies.
• Xencor's collaborations with larger pharmaceutical companies have yielded significant upfront and milestone payments, setting a high benchmark for Cue Biopharma to aspire to.
• Compass Therapeutics has focused on antibody therapeutics, providing a different approach to modulating the immune system compared to Cue Biopharma's Immuno-STAT platform.

Stakeholder Impact

• Shareholders will be impacted by the capital raise and the potential value creation from the Boehringer Ingelheim collaboration.
• Employees may benefit from the increased financial stability and the advancement of the company's programs.
• Patients with autoimmune diseases and cancer could potentially benefit from the development of new therapies based on Cue Biopharma's Immuno-STAT platform.

Next Steps

• Advance CUE-401 toward the clinic.
• Explore additional portfolio optimization and partnering opportunities.
• Host a virtual event on May 15, 2025, to discuss CUE-401 and other programs.

Key Dates

Keywords

Cue Biopharma, CUE-501, CUE-401, Boehringer Ingelheim, Financial Results, Collaboration, Capital Raise, Immunology, Biopharmaceutical, Clinical-Stage